Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients

European Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 43-50

  Somparn, Nuntiya ^a   Kukongviriyapan, Upa ^a   Tassaneeyakul, Wichittra ^a   Jetsrisuparb, Arunee ^a   Kukongviriyapan, Veerapol ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

CYP2E1; CYP3A4; Growth hormone; Hypersplenism; Oxidative stress; Thalassemia

Indexed keywords

6 HYDROXYCHLORZOXAZONE; 6BETA HYDROXYHYDROCORTISONE; ANTIOXIDANT; CARBONYL DERIVATIVE; CHLORZOXAZONE; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUTATHIONE; GROWTH HORMONE; HEMOGLOBIN E; HYDROCORTISONE; IRON; LIPID; NITRIC OXIDE; OXIDIZING AGENT; PROTEIN;

ANALYTICAL PARAMETERS; ARTICLE; BETA THALASSEMIA; BIOCHEMISTRY; BLOOD LEVEL; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME MODIFICATION; FEMALE; GLUTATHIONE METABOLISM; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE URINE LEVEL; IRON BLOOD LEVEL; IRON CHELATION; LIPID PEROXIDATION; MALE; METABOLITE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; SCHOOL CHILD; SPLENECTOMY; URINALYSIS;

ANTIOXIDANTS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEMOGLOBIN E; HUMANS; MALE; OXIDATIVE STRESS; SPLENECTOMY; THAILAND;

EID: 33845879354     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0224-x     Document Type: Article

References (42)

1. Tanaka E (1998) Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. J Clin Pharm Ther 23:161-170
2. George J, Byth K, Farrell GC (1996) Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol 11:33-39
3. Cederbaum AI (2003) Iron and CYP2E1-dependent oxidative stress and toxicity. Alcohol 30:115-120
4. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ (2002) Mechanisms of hepatotoxicity. Toxicol Sci 65:166-176
5. Weatherall DJ (2000) Introduction to the problem of hemoglobin E-beta thalassemia. J Pediatr Hematol Oncol 22:551
6. Shinar E, Rachmilewitz EA (1990) Oxidative denaturation of red blood cells in thalassemia. Semin Hematol 27:70-82
7. Weatherall DJ (1998) Pathophysiology of thalassaemia. Baillieres Clin Haematol 11:127-146
8. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187-1193
9. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR (2004) Complications of beta-thalassemia major in North America. Blood 104:34-39
10. Gulati R, Bhatia V, Agarwal SS (2000) Early onset of endocrine abnormalities in beta-thalassemia major in a developing country. J Pediatr Endocrinol Metab 13:651-656
11. Levitsky LL, Schoeller DA, Lambert GH, Edidin DV (1989) Effect of growth hormone therapy in growth hormone-deficient children on cytochrome P-450-dependent 3-N-demethylation of caffeine as measured by the caffeine 13CO2 breath test. Dev Pharmacol Ther 12:90-95
12. Sinues B, Mayayo E, Fanlo A, Mayayo E Jr, Bernal ML, Bocos P, Bello E, Labarta JI, Ferrandez-Longas A (2004) Effects of growth hormone deficiency and rhGH replacement therapy on the 6beta-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children. Eur J Clin Pharmacol 60: 559-564
13. Oinonen T, Lindros KO (1995) Hormonal regulation of the zonated expression of cytochrome P-450 3A in rat liver. Biochem J 309:55-61
14. Aessopos A, Farmakis D, Tsironi M, Deftereos S, Tassiopoulos S, Konstantopoulos K, Rombos J, Papalambros E (2004) Hemodynamic assessment of splenomegaly in beta-thalassemia patients undergoing splenectomy. Ann Hematol 83:775-778
15. Garnett ES, Goddard BA, Markby D, Webber CE (1969) The spleen as an arteriovenous shunt. Lancet 1:386-388
16. Li CK, Chik KW, Lam CW, To KF, Yu SC, Lee V, Shing MM, Cheung AY, Yuen PM (2002) Liver disease in transfusion dependent thalassaemia major. Arch Dis Child 86:344-347
17. Frye RF, Stiff DD (1996) Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 686:291-296
18. Homma M, Beckerman K, Hayashi S, Jayewardene AL, Oka K, Gambertoglio JG, Aweeka FT (2000) Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women. J Pharm Biomed Anal 23:629-635
19. Galteau MM, Shamsa F (2003) Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713-733
20. Draper HH, Squires EJ, Mahmoodi H, Wu J, Agarwal S, Hadley M (1993) A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med 15:353-363
21. Verdon CP, Burton BA, Prior RL (1995) Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite. Anal Biochem 224:502-508
22. Reznick AZ, Packer L (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 233:357-363
23. Banerjee D, Jacob J, Kunjamma G, Madhusoodanan UK, Ghosh S (2004) Measurement of urinary hydrogen peroxide by FOX-1 method in conjunction with catalase in diabetes mellitus-a sensitive and specific approach. Clin Chim Acta 350:233-236
24. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN (2002) Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51:174-181
25. Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502-522
26. Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA (1998) Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 38:82-89
27. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105:1067-1075
28. Chakraborty D, Bhattacharyya M (2001) Antioxidant defense status of red blood cells of patients with beta-thalassemia and Ebeta-thalassemia. Clin Chim Acta 305:123-129
29. Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, Amri F, Selmi H, Bejaoui M, Miled A (2003) Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta 338:79-86
30. Pahan K, Smith BT, Singh AK, Singh I (1997) Cytochrome P-450 2E1 in rat liver peroxisomes: downregulation by ischemia/reperfusion-induced oxidative stress. Free Radic Biol Med 23:963-971
31. Hakkola J, Hu Y, Ingelman-Sundberg M (2003) Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J Pharmacol Exp Ther 304:1048-1054
32. Stal P, Johansson I, Ingelman-Sundberg M, Hagen K, Hultcrantz R (1996) Hepatotoxicity induced by iron overload and alcohol. Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation. J Hepatol 25:538-546
33. Lieber CS (1997) Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 77:517-544
34. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M (2004) Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 73:359-366
35. Liangpunsakul S, Kolwankar D, Pinto A, Gorski JC, Hall SD, Chalasani N (2005) Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology 41:1144-1150
36. Takagi K, Ashida H, Utsunomiya J (1994) The effect of splenomegaly on splanchnic hemodynamics in nonalcoholic cirrhosis after distal splenorenal shunt and splenopancreatic disconnection. Hepatology 20:342-348
37. Charmandari E, Johnston A, Brook CG, Hindmarsh PC (2001) Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Endocrinol 169:65-70
38. Burk O, Wojnowski L (2004) Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 369: 105-124
39. Redmond GP, Bell JJ, Nichola PS, Perel JM (1980) Effect of growth hormone on human drug metabolism: time course and substrate specificity. Pediatr Pharmacol (New York) 1:63-70
40. Dhir RN, Dworakowski W, Thangavel C, Shapiro BH (2006) Sexually dimorphic regulation of hepatic isoforms of human cytochrome p450 by growth hormone. J Pharmacol Exp Ther 316:87-94
41. Wenk M, Todesco L, Krahenbuhl S (2004) Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xantine oxidase in healthy males and females. Br J Clin Pharmacol 57:495-499
42. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184